https://www.streetinsider.com/Corporate%2BNews/Allergan%2B%2528AGN%2529%2BAnnounces%2BFDA%2BApproval%2BFor%2BUse%2Bof%2BVRAYLAR%2Bin%2BMaintenance%2BTreatment%2Bof%2BSchizophrenia/13494423.html

As you were browsing www.streetinsider.com something about your browser made us think you were a bot. If you are interested in www.streetinsider.com content, APIs are available.  Please contact us here http://www.streetinsider.com/signup_content.php To request an unblock, please fill out the form below and we will review it as soon as possible. 

https://investorplace.com/2017/11/allergan-agn-a-sell-on-sinking-industry-group-rank/

Allergan Inc (NYSE:AGN) is ranked as a Sell using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking AGN has had from Portfolio Grader for 4 months. As one of the 785 companies in the GICS Health Care sector AGN is a constituent of the 133 company Pharmaceuticals GICS industry group within this sector. AGN's market value is $58.2 billion which places it in the top 10% of its industry group The current Portfolio Grader ranking for AGN puts it 96 among the 133 companies in this industry group, giving it a below-average spot. The Health Care sector is ranked number 10 among the 12 sectors in the Portfolio Grader universe putting it in the bottom quartile of all the GICS sectors. The Pharmaceuticals industry group is ranked 53 among the 69 industry groups within the GICS sectors, placing it well below-average in terms of the Navellier scoring system. The company scores are below-average in 7 of the 8 fundamental metrics used by Portfolio Grader in the ranking of company stocks. AGN's operational scores provide mixed results with a ranking for operating margin that is below-average, a ranking for earnings growth that is well below average, and a score for sales growth that is above average. Scores for visibility of earnings are a source of great concern with a ranking for earnings revisions, earnings surprises and earnings momentum that are worse than average. AGN's metrics for cash flow and return on equity are worse than its industry group average. These fundamental scores give Allergan a position in the bottom quartile of the industry group.  Quantitatively, Portfolio Grader uses the Navellier Proprietary Quantitative Score to view AGN's shares from the aspect of risk/reward. This proprietary scoring methodology weighs the relative value of AGN's shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Based on this risk/reward calculation, the company currently scores below-average in its industry group compared to its peers. Louis Navellier's proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being 'strong buy' and F being 'strong sell'.  Explore the tool here. Commentary provided by UpTick Data Technologies. Article printed from InvestorPlace Media, https://investorplace.com/2017/11/allergan-agn-a-sell-on-sinking-industry-group-rank/. ©2017 InvestorPlace Media, LLC 

https://simplywall.st/news/2017/11/13/allergan-plc-agn-what-you-have-to-know-before-buying-for-the-upcoming-dividend/

 Shares of Allergan plc (NYSE:AGN) will begin trading ex-dividend in 3 days. To qualify for the dividend check of $0.7 per share, investors must have owned the shares prior to 16 November 2017, which is the last day the company’s management will finalize their list of shareholders to which they will send dividend payments. Is this future income a persuasive enough catalyst for investors to think about AGN as an investment today? Below, I’m going to look at the latest data and analyze the stock and its dividend property in further detail. Check out our latest analysis for Allergan   When researching a dividend stock, I always follow the following screening criteria:  

https://www.truebluetribune.com/2017/11/13/allergan-plc-announces-quarterly-dividend-of-0-70-agn.html


					Posted by Ken Jordan on Nov 13th, 2017 // No Comments  Allergan PLC. (NYSE:AGN) announced a quarterly dividend on Friday, October 27th, RTT News reports. Stockholders of record on Friday, November 17th will be paid a dividend of 0.70 per share on Friday, December 15th. This represents a $2.80 annualized dividend and a dividend yield of 1.63%. The ex-dividend date is Thursday, November 16th.  Allergan PLC. has a payout ratio of 17.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Allergan PLC. to earn $16.24 per share next year, which means the company should continue to be able to cover its $2.80 annual dividend with an expected future payout ratio of 17.2%.  Shares of Allergan PLC. (NYSE AGN) traded down €0.79 ($0.92) during trading hours on Friday, hitting €172.21 ($200.24). The stock had a trading volume of 3,250,000 shares, compared to its average volume of 5,736,873. The stock has a market cap of $57,274.12, a price-to-earnings ratio of 11.17, a price-to-earnings-growth ratio of 1.09 and a beta of 1.13. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. Allergan PLC. has a fifty-two week low of €169.64 ($197.26) and a fifty-two week high of €256.80 ($298.60).  Allergan PLC. (NYSE:AGN) last posted its earnings results on Wednesday, November 1st. The company reported €4.15 ($4.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of €4.06 ($4.72) by €0.09 ($0.10). Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm had revenue of €4.03 billion for the quarter, compared to analyst estimates of €4.04 billion. During the same quarter in the prior year, the company earned $3.32 EPS. Allergan PLC.’s revenue was up 11.4% on a year-over-year basis.  sell-side analysts expect that  Allergan PLC. will post 16.28 EPS for the current year.  Allergan PLC. announced that its board has initiated a share repurchase plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in  outstanding  shares. This repurchase authorization authorizes the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board believes its shares are undervalued.  COPYRIGHT VIOLATION WARNING: This article was  posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.truebluetribune.com/2017/11/13/allergan-plc-announces-quarterly-dividend-of-0-70-agn.html.  A number of research analysts have weighed in on the company. Wells Fargo & Company  reissued an “outperform” rating and set a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. UBS AG  reissued an “outperform” rating and set a $275.00 price target on shares of Allergan PLC. in a research note on Wednesday, August 9th. Piper Jaffray Companies  set a $227.00 price target on Allergan PLC. and gave the stock a “hold” rating in a research note on Friday, October 13th. Argus  restated a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a report on Monday, August 14th. Finally, BidaskClub downgraded Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. One equities research analyst  has rated the stock with a sell rating, eleven have assigned  a hold rating and twelve have assigned  a buy rating to the stock. Allergan PLC.  has a consensus rating of “Hold” and an average target price of €246.73 ($286.90). About Allergan PLC. Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womens health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimers disease.   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

https://economicsandmoney.com/2017/11/10/a-look-into-insider-activity-with-allergan-plc-agn-2/

Allergan plc (NYSE:AGN) has seen its stock price gain 37.01, or -17.62%, so far in 2017. In the past 3-month period alone, shares of AGN have appreciated -64.97 – or -27.30%. The stock’s 52-week range is $169.64 to $256.80, and its 3-month range is $169.64 to $237.84. The average Wall Street analyst rating for Allergan plc is Hold, according to the average of 16 analyst scores. Of those analysts, 7 rate stock as a Strong Buy, 7 rate it as Hold, and just no analyst rates it as a Moderate Sell. Insider Trading Activity for Allergan plc Taking a look at insider trading at Allergan plc (NYSE:AGN) can give useful insight into how the stock is performing. Allergan plc has had 0 insider trades in the last 3 months, including 0 open market buys and 0 sells. Of those insider trades, 0 shares of Allergan plc were purchased and 0 shares were sold. The total number of shares traded in the last 90-day period is 0. 
     (adsbygoogle = window.adsbygoogle || []).push({});
 Insider trading over the last 12 months, however, paints a different picture. In the last year there have been a total of 64 insider trades, including 33 open market buys and 31 sells. Of those transactions, there were 101,972 shares of AGN bought and 106,260 shares sold. The total number of shares traded in the last 12 months is 208,232. The most recent open market insider trade was Buy of 44 shares on a day where the closing price was 235.96. The insider, SAUNDERS BRENT L, now holds 131,178 shares of AGN. The most recent non open market insider trade was completed by NICHOLSON C. DAVID on 08/04/2017, and was a disposition of 3,898 shares with a final price of $242.65. The insider now holds 13,040 shares of Allergan plc (AGN). Examining Institutional Ownership at Allergan plc (NYSE:AGN) According to Allergan plc’s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 85.03%. The total amount of shares outstanding is 335.19 million, giving the company a market capitalization of about 57.99 billion. There are 1,223 institutional holders with active positions, accounting for 282.78 million shares in total. Of those holders, 557 had increased positions amounting to 19.19 million shares, 529 had decreased positions amounting to 25.71 million shares, and 137 holders have a held position accounting for 237.89 million shares. The top 5 institutional holders, in ascending order, are as follows: VANGUARD GROUP INC with 22.84 million shares, WELLINGTON MANAGEMENT GROUP LLP with 20.7 million shares, BLACKROCK INC. with 19.92 million shares, STATE STREET CORP with 15.59 million shares, and FMR LLC with 13.28 million shares. According to Allergan plc (AGN) most recent 13F filing, the company has 99 new institutional holders – accounting for 2.48 million shares of its common stock. There were 102 sold out positions, amounting to 2.26 million shares. 



(adsbygoogle = window.adsbygoogle || []).push({});
 

https://www.dispatchtribunal.com/2017/11/12/c-worldwide-group-holding-a-s-lowers-position-in-allergan-plc-agn.html


					Posted by Mickey Rousseau on Nov 12th, 2017 // No Comments  C WorldWide Group Holding A S trimmed its position in shares of  Allergan PLC. (NYSE:AGN) by 3.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,086 shares of the company’s stock after selling 3,704 shares during the period. C WorldWide Group Holding A S’s holdings in Allergan PLC. were worth $19,488,000 at the end of the most recent quarter.  Other institutional investors and hedge funds have also recently modified their holdings of the company. Pathstone Family Office LLC boosted its holdings in  Allergan PLC. by 3,327.3% during the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock valued at $2,035,000 after purchasing an additional 366 shares in the last quarter.  Howard Hughes Medical Institute acquired a new stake in  Allergan PLC. during the second quarter valued at approximately $103,000.  Jacobi Capital Management LLC boosted its holdings in  Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares in the last quarter.  Massey Quick & Co. LLC boosted its holdings in  Allergan PLC. by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares in the last quarter.  Finally, Cable Hill Partners LLC boosted its holdings in  Allergan PLC. by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after purchasing an additional 370 shares in the last quarter. Hedge funds and other institutional investors own  82.14% of the company’s stock.  Shares of Allergan PLC. (AGN) traded down €0.79 ($0.92) during trading on Friday, hitting €172.21 ($200.24). 3,250,000 shares of the company’s stock traded hands, compared to its average volume of 5,736,873. The company has a market cap of $57,274.12, a PE ratio of 11.17, a price-to-earnings-growth ratio of 1.09 and a beta of 1.13. Allergan PLC. has a 52 week low of €169.64 ($197.26) and a 52 week high of €256.80 ($298.60). The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40.  Allergan PLC. (NYSE:AGN) last issued its earnings results on Wednesday, November 1st. The company reported €4.15 ($4.83) EPS for the quarter, beating the consensus estimate of €4.06 ($4.72) by €0.09 ($0.10). The company had revenue of €4.03 billion during the quarter, compared to analysts’ expectations of €4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.32 EPS.  research analysts forecast that  Allergan PLC. will post 16.28 earnings per share for the current fiscal year.  The firm also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.63%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s payout ratio is -12.44%.  Allergan PLC. announced that its Board of Directors has approved a stock repurchase plan on Monday, September 25th that allows the company to buyback $2.00 billion in    shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock  through open market purchases. Stock  buyback plans are generally a sign that the company’s board believes its stock is undervalued.  A number of research firms have weighed in on AGN. UBS AG  reaffirmed an “outperform” rating and set a $275.00 price objective on shares of Allergan PLC. in a report on Wednesday, August 9th. BidaskClub downgraded Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Wells Fargo & Company  reaffirmed an “outperform” rating and set a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Royal Bank Of Canada decreased their price objective on Allergan PLC. from $250.00 to $221.00 and set an “outperform” rating on the stock in a report on Thursday, November 2nd. Finally, Argus  reaffirmed a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a report on Monday, August 14th. One research analyst  has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the stock. The company  has a consensus rating of “Hold” and a consensus target price of €246.73 ($286.90). Allergan PLC. Profile Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womens health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimers disease. Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

https://ledgergazette.com/2017/11/12/allergan-plc-agn-shares-sold-by-c-worldwide-group-holding-a-s.html


					Posted by Jennifer Salazar on Nov 12th, 2017 // No Comments  C WorldWide Group Holding A S reduced its stake in  Allergan PLC. (NYSE:AGN) by 3.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,086 shares of the company’s stock after selling 3,704 shares during the quarter. C WorldWide Group Holding A S’s holdings in Allergan PLC. were worth $19,488,000 at the end of the most recent reporting period.  Other institutional investors also recently added to or reduced their stakes in the company. Hudock Capital Group LLC increased its holdings in shares of  Allergan PLC. by 0.4% during the second quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after purchasing an additional 2 shares during the period.  Burns J W & Co. Inc. NY increased its holdings in shares of  Allergan PLC. by 0.7% during the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after purchasing an additional 6 shares during the period.  Pacific Center for Financial Services increased its holdings in shares of  Allergan PLC. by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the period.  Gilder Gagnon Howe & Co. LLC increased its holdings in shares of  Allergan PLC. by 0.5% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after purchasing an additional 9 shares during the period.  Finally, Trust Co increased its holdings in shares of  Allergan PLC. by 0.8% during the first quarter. Trust Co now owns 1,224 shares of the company’s stock worth $292,000 after purchasing an additional 10 shares during the period. 82.14% of the stock is currently owned by hedge funds and other institutional investors.  TRADEMARK VIOLATION NOTICE: This piece was originally  reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://ledgergazette.com/2017/11/12/allergan-plc-agn-shares-sold-by-c-worldwide-group-holding-a-s.html.  Shares of Allergan PLC. (AGN) traded down €0.79 ($0.92) during trading hours on Friday, hitting €172.21 ($200.24). 3,250,000 shares of the stock were exchanged, compared to its average volume of 5,736,873. The firm has a market capitalization of $57,274.12, a price-to-earnings ratio of 11.17, a PEG ratio of 1.09 and a beta of 1.13. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Allergan PLC. has a 52 week low of €169.64 ($197.26) and a 52 week high of €256.80 ($298.60).  Allergan PLC. (NYSE:AGN) last issued its quarterly earnings results on Wednesday, November 1st. The company reported €4.15 ($4.83) EPS for the quarter, topping analysts’ consensus estimates of €4.06 ($4.72) by €0.09 ($0.10). The company had revenue of €4.03 billion for the quarter, compared to analyst estimates of €4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. Allergan PLC.’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.32 earnings per share.  research analysts anticipate that  Allergan PLC. will post 16.28 earnings per share for the current fiscal year.  The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be issued a dividend of $0.70 per share. The ex-dividend date is Thursday, November 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.63%. Allergan PLC.’s dividend payout ratio (DPR) is presently -12.44%.  Allergan PLC. declared that its Board of Directors has approved a share repurchase program on Monday, September 25th that allows the company to buyback $2.00 billion in  outstanding  shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock  through open market purchases. Stock  buyback programs are usually an indication that the company’s board believes its shares are undervalued.  AGN has been the topic of several recent research reports. Argus  reaffirmed a “buy” rating and set a $280.00 target price on shares of Allergan PLC. in a report on Monday, August 14th. Deutsche Bank AG  reaffirmed a “buy” rating and set a $273.00 target price (up from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Royal Bank Of Canada  set a $284.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Sunday, July 16th. Mizuho  reaffirmed a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a report on Wednesday, August 2nd. Finally, Credit Suisse Group  set a $288.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Saturday, August 5th. One equities research analyst  has rated the stock with a sell rating, eleven have issued  a hold rating and twelve have assigned  a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of €246.73 ($286.90). Allergan PLC. Profile Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womens health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimers disease. Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

https://news4j.com/2017/11/10/mining-down-the-detailed-statistics-for-todays-share-market-allergan-plc-agn/


Adam Costello 
3 days ago
Ticker Updates
Leave a comment
 Allergan plc | (NYSE:AGN) | Friday, November 10, 2017 The top gainer with a security that increased in price during today’s trading was Allergan plc (NYSE:AGN). Allergan plc had a higher price at the close than it did at the open. The company holds a market cap of 57.99B with a P/E of *tba indicating whether its share price properly reflects its performance. Fundamentalists and value investors are seeing the low ratio of 3.75 as more positive – demonstrating that the company has a great deal of revenue with a fair price. However, technicians believes that a higher ratio would indicate the likelihood of a constant augmentation of the company’s share price. Allergan plc’s P/B is valued at 0.87 exhibiting the investor sentiment on the value of the stock to its actual value. A higher P/B ratio of Allergan plc is signposting that the investors have either overvalued it , or that its accountants have undervalued it. The P/B figure is also providing some ideas on whether the shareholders are paying too much for what would be left if the company went bankrupt immediately – but to consider that the company ought to have a lower P/B value. As of now, the increased share price of Allergan plc makes it a lucrative buy for investors. A change of -1.15% in the price clearly indicates a strong asset performance for the corporation, , bearing in mind the total returns from its investment and dividends or distributions obtained from the investment. The ROA of Allergan plc is currently valued at -6.00% indicating how profitable the company is in regards to its total assets. The figure tells us what earnings were generated from invested capital of Allergan plc. It gives investors a clue on how effective the company is in converting the money it has to invest into net income. Allergan plc’s ROI is valued at 0.10% relatively measuring the profitability on the investment. It evidently points out how profitable and preferable it is for the investors. The company has a current ratio of 1.2 gauging towards its ability in paying short-term and long-term obligations. With the existing current ratio, Allergan plc is more than equipped to confront its liabilities with its assets. Allergan plc has a quick ratio of 1.1 measuring its ability to meet its short term obligations with its most liquid assets. The high quick ratio specifies its better liquidity position on the credit terms the company has negotiated from its suppliers. The EPS growth this year is at 63.30% demonstrating an EPS growth of -0.84% in the coming year. This defines the most likely future of the stock price of Allergan plc. With this high EPSGR it is predicted that growth rate will rise faster as compared to its competitors in the same industry. As it upholds an amended rate with more EPSGR it is prone to be a good target. Allergan plc NYSE : AGN | Friday, November 10, 2017    Tags (NYSE:AGN) AGN Allergan plc Drugs - Generic Healthcare NYSE 5 mins ago 5 mins ago 5 mins ago Your email address will not be published. Required fields are marked * Comment  Name *  Email *  Website   

 

https://www.dispatchtribunal.com/2017/11/12/c-worldwide-group-holding-a-s-lowers-position-in-allergan-plc-agn.html


					Posted by Mickey Rousseau on Nov 12th, 2017 // No Comments  C WorldWide Group Holding A S trimmed its position in shares of  Allergan PLC. (NYSE:AGN) by 3.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,086 shares of the company’s stock after selling 3,704 shares during the period. C WorldWide Group Holding A S’s holdings in Allergan PLC. were worth $19,488,000 at the end of the most recent quarter.  Other institutional investors and hedge funds have also recently modified their holdings of the company. Pathstone Family Office LLC boosted its holdings in  Allergan PLC. by 3,327.3% during the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock valued at $2,035,000 after purchasing an additional 366 shares in the last quarter.  Howard Hughes Medical Institute acquired a new stake in  Allergan PLC. during the second quarter valued at approximately $103,000.  Jacobi Capital Management LLC boosted its holdings in  Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares in the last quarter.  Massey Quick & Co. LLC boosted its holdings in  Allergan PLC. by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares in the last quarter.  Finally, Cable Hill Partners LLC boosted its holdings in  Allergan PLC. by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after purchasing an additional 370 shares in the last quarter. Hedge funds and other institutional investors own  82.14% of the company’s stock.  Shares of Allergan PLC. (AGN) traded down €0.79 ($0.92) during trading on Friday, hitting €172.21 ($200.24). 3,250,000 shares of the company’s stock traded hands, compared to its average volume of 5,736,873. The company has a market cap of $57,274.12, a PE ratio of 11.17, a price-to-earnings-growth ratio of 1.09 and a beta of 1.13. Allergan PLC. has a 52 week low of €169.64 ($197.26) and a 52 week high of €256.80 ($298.60). The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40.  Allergan PLC. (NYSE:AGN) last issued its earnings results on Wednesday, November 1st. The company reported €4.15 ($4.83) EPS for the quarter, beating the consensus estimate of €4.06 ($4.72) by €0.09 ($0.10). The company had revenue of €4.03 billion during the quarter, compared to analysts’ expectations of €4.04 billion. Allergan PLC. had a negative net margin of 47.27% and a positive return on equity of 8.00%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.32 EPS.  research analysts forecast that  Allergan PLC. will post 16.28 earnings per share for the current fiscal year.  The firm also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.63%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s payout ratio is -12.44%.  Allergan PLC. announced that its Board of Directors has approved a stock repurchase plan on Monday, September 25th that allows the company to buyback $2.00 billion in    shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock  through open market purchases. Stock  buyback plans are generally a sign that the company’s board believes its stock is undervalued.  A number of research firms have weighed in on AGN. UBS AG  reaffirmed an “outperform” rating and set a $275.00 price objective on shares of Allergan PLC. in a report on Wednesday, August 9th. BidaskClub downgraded Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Wells Fargo & Company  reaffirmed an “outperform” rating and set a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Royal Bank Of Canada decreased their price objective on Allergan PLC. from $250.00 to $221.00 and set an “outperform” rating on the stock in a report on Thursday, November 2nd. Finally, Argus  reaffirmed a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a report on Monday, August 14th. One research analyst  has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the stock. The company  has a consensus rating of “Hold” and a consensus target price of €246.73 ($286.90). Allergan PLC. Profile Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womens health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimers disease. Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).   Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter. 

http://www.nasdaq.com/article/allergan-agn-beats-q3-earnings-sales-in-line-stock-up-cm869326

 Dublin, Ireland-based Allergan plc AGN  is engaged in the development, manufacturing, marketing, sale and distribution of branded pharmaceuticals device, biologic, surgical and regenerative medicine products. Allergan has been actively pursuing deals to expand its portfolio especially its branded products offering. Having completed the acquisition of companies like Durata and Forest, Allergan acquired Botox maker, Allergan Inc., in Mar 2015. With this acquisition, Allergan, which was previously known for its strong presence in the generics market, finds itself in the company of the top 10 pharmaceutical companies across the world based on sales. In 2017 so far, through the accretive acquisitions of LifeCell and ZELTIQ, Allergan has expanded its medical aesthetics business into regenerative medicine and body sculpting, respectively. Allergan sold its generics and Anda distribution business to Teva in Aug and Oct 2016, respectively. Allergan's earnings performance has been mixed so far, with the company beating expectations in three of the past four quarters and missing on one occasion. The average negative earnings surprise over the last four quarters is 0.36%. Currently, Allergan has a Zacks Rank #4 (Sell), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:  Earnings Beat:  Allergan's third-quarter earnings of $4.15 per share were above our consensus estimate of $4.06 per share.  Revenues In Line:  Revenues came in at $4.03 billion, up 11.4% from the year-ago period, and in line with the Zacks Consensus Estimate.  2017 Outlook:  The company narrowed its previously issued earnings and sales guidance for 2017. Allergan expects total revenue in the range of $15.875 billion to $16.025 billion compared with $15.85 billion to $16.05 billion previously. Adjusted earnings per share are expected in the range of $16.15-$16.45 compared with $16.05-$16.45 previously.  Share Price Impact:  Shares were up more than 2% in  pre-market trading  . Check back later for our full write up on this AGN earnings report later !   More Stock News: This Is Bigger than the   iPhone!                       It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.    Click here for the 6 trades >>     Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report makeArticleAd();  Allergan PLC. (AGN): Free Stock Analysis Report   To read this article on Zacks.com click here.   Zacks Investment Research  Dublin, Ireland-based Allergan plc AGN  is engaged in the development, manufacturing, marketing, sale and distribution of branded pharmaceuticals device, biologic, surgical and regenerative medicine products. Allergan has been actively pursuing deals to expand its portfolio especially its branded products offering. Having completed the acquisition of companies like Durata and Forest, Allergan acquired Botox maker, Allergan Inc., in Mar 2015. With this acquisition, Allergan, which was previously known for its strong presence in the generics market, finds itself in the company of the top 10 pharmaceutical companies across the world based on sales. In 2017 so far, through the accretive acquisitions of LifeCell and ZELTIQ, Allergan has expanded its medical aesthetics business into regenerative medicine and body sculpting, respectively. Allergan sold its generics and Anda distribution business to Teva in Aug and Oct 2016, respectively. Allergan's earnings performance has been mixed so far, with the company beating expectations in three of the past four quarters and missing on one occasion. The average negative earnings surprise over the last four quarters is 0.36%. Currently, Allergan has a Zacks Rank #4 (Sell), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:  Earnings Beat:  Allergan's third-quarter earnings of $4.15 per share were above our consensus estimate of $4.06 per share.  Revenues In Line:  Revenues came in at $4.03 billion, up 11.4% from the year-ago period, and in line with the Zacks Consensus Estimate.  2017 Outlook:  The company narrowed its previously issued earnings and sales guidance for 2017. Allergan expects total revenue in the range of $15.875 billion to $16.025 billion compared with $15.85 billion to $16.05 billion previously. Adjusted earnings per share are expected in the range of $16.15-$16.45 compared with $16.05-$16.45 previously.  Share Price Impact:  Shares were up more than 2% in  pre-market trading  . Check back later for our full write up on this AGN earnings report later !   More Stock News: This Is Bigger than the   iPhone!                       It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.    Click here for the 6 trades >>   
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
 

 

